The DCI Office of Health Equity hosted a clinical trials primer for the community led by Angelo Moore, PhD, RN, in partnership with the Durham Men's Health Council. (5.18)
For some patients, targeted therapy is their best shot. The Molecular Tumor Board at DCI is matching more and more patients to approved therapies and clinical trials.
When Duke Cancer Institute researcher Christopher Pirozzi, PhD, was an intern doing stem cell research in Australia, he spotted a child’s mobile of a ...
On Wednesday, Sept. 28, Matthias Gromeier, MD; Eric Thompson, MD; and Darell Bigner, MD, PhD; received a check for $208,408 from The Andrew McDonough ...
Susan Boulton, RN, BSN, previously assistant research practice manager (ARPM) with The Preston Robert Tisch Brain Tumor Center (PRTBTC), was recently ...
Yousuf Zafar, MD, MHS, and healthcare technology company Vivor are the recent recipients of a National Institutes of Health/National Cancer Institute ...
Driver, a global technology platform that connects cancer patients to the best treatments, recently launched in the United States and China. Driver’s ...
The Office of Health Equity (OHE) will host 50 Hoops, a panel discussion on barriers to enrollment in clinical trials, on Thursday, Nov. 8, from 5 to ...
The recombinant poliovirus therapy developed at the Preston Robert Tisch Brain Tumor Center at Duke Health has been granted “breakthrough therapy desi...
After the loss of her dad, Don Painter, in 2014 to colon cancer, Wanda P. Honeycutt, RN, BSN, CCRP, began running. She participated in her first compe...
Join us at facebook.com/dukecancerinstitute on Wednesday, May 1, at noon for a live panel discussion featuring cancer survivor and cycling enthusiast ...